The Competition Commission of India has reportedly stepped up scrutiny of the proposed merger between Sun Pharmaceutical Industries and Ranbaxy Laboratories.
The CCI is said to have approached the companies asking they the authority shouldn’t launch an investigation; the regulator also reportedly said the merger would result in significant market strength by one company and could affect the costs of crucial drugs within India.
The CCI issued a show-cause notice to each of the companies, according to unnamed officials at the antitrust watchdog. According to reports, the notices mark the first-ever instance that the CCI has referenced national interest to question a proposed merger.
The $3.2 billion merger will need to secure approval by the CCI, various Indian courts, and the Securities and Exchange Board of India.
Full content: Live Mint
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Lawmaker Probes FTC and EU’s Role in Amazon’s Failed iRobot Acquisition
May 2, 2024 by
CPI
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Healthcare Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI